XERS Xeris Biopharma Holdings, Inc.

NEUTRAL Impact: 2/10 144
Horizon days Filed Jun 4, 2026 Processed 12d 11h ago SEC 0001950047-26-005664
Form 144 — notice of proposed sale of securities
Latest settled — T+5d
XERS ▲ +9.87% at T+5d
NEUTRAL call ✓ call won +9.87% · α vs SPY +9.30% · entry $6.18 → $6.79
Next anchor: T+20d in 16d
Currently $6.90 · +11.65% from $6.18 entry
Entry anchored
Jun 4, 2026
via day open
T+1d
+0.97%
call +0.97% · α +0.74%
$6.24
settled 12d ago
T+5d
+9.87%
call +9.87% · α +9.30%
$6.79
settled 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma common stock, with an estimated aggregate market value of $117,800. The shares were acquired via restricted stock unit vesting on June 3, 2026. This is a relatively small proposed sale relative to the company's $1.0B market cap and represents a routine diversification move by a director, not a material signal of insider concern.

Actionable Insight

This is a routine director diversification sale following RSU vesting. The dollar amount is negligible relative to market cap. No actionable signal for traders — monitor for any follow-on insider selling patterns in future Form 4 filings.

Key Facts

  • Director Dawn Halkuff filed Form 144 to sell 20,000 shares of XERS common stock.
  • Estimated aggregate market value of the proposed sale is $117,800.
  • Shares were acquired via restricted stock unit vesting on June 3, 2026.
  • The sale represents approximately 0.012% of the company's $1.0B market cap.
  • The filing is an advance notice of intent to sell; the sale may not be executed.

Financial Impact

Proposed sale of $117,800 in XERS common stock by a director — immaterial relative to $1.0B market cap.

dilution

Risk Factors

  • If the sale is executed, it could be followed by additional insider sales, though the current amount is too small to be concerning.
  • No other material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005664
Document: 0001950047-26-005664-index.html0001950047-26-005664
Document: 0001950047-26-005664.txt0001950047-26-005664
6 reports for XERS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for XERS — sortable, filterable
Type Now
Jun 12, 2026
4d ago
Institutional Cluster
BULLISH ★ 4/10
$6.79 $6.88▲ +1.33%▼ −0.44%$6.90 (+1.62%)
Jun 5, 2026
11d ago
Insider Cluster
NEUTRAL ★ 3/10
$6.24 $6.50▲ +4.17%▲ +4.46%$6.90 (+10.58%)
Jun 5, 2026
11d ago
Insider Cluster
NEUTRAL ★ 3/10
$6.24 $6.50▲ +4.17%▲ +4.46%$6.90 (+10.58%)
Jun 4, 2026
12d ago
144
NEUTRAL ★ 2/10
$6.18 $6.24▲ +0.97%▲ +0.74%$6.90 (+11.65%)
Jun 3, 2026
13d ago
144
NEUTRAL ★ 2/10
$6.15 $6.18▲ +0.49%▲ +3.06%$6.90 (+12.20%)
Feb 27, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$6.12 $6.02▼ −1.63%▼ −1.69%$6.90 (+12.75%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 5h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access